|Drug class||Nonsteroidal antiandrogen|
|Chemical and physical data|
|Molar mass||305.213 g/mol g·mol−1|
|3D model (JSmol)|
RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed. It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis. Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.
- Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol. Ther. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-x. PMID 6205409.
- Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
- Thomson, D. S. (1989). "Pharmacology of Anti-androgens in the Skin". 87 / 2: 483–493. doi:10.1007/978-3-642-74054-1_36. ISSN 0171-2004. Cite journal requires
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|